Humacyte Secures U.S. Patent For Bioengineered Esophagus Composition Using Proprietary Regenerative Tissue Engineering Platform

– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus –

– Patent provides coverage into 2041 for the composition of novel bioengineered esophagus –

DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowance of a U.S. Patent covering the composition of a bioengineered esophagus that can be produced using the Company's proprietary regenerative tissue engineering platform. The patent, titled "Tubular Prostheses (Esophagus)," provides protection into 2041 of key structural and mechanical attributes for its designed use as an esophageal replacement including size, strength, and methods of production. Humacyte's Tubular Prostheses patent family encompasses composition and methods claims for advanced tissue constructs intended to replace damaged airways, upper digestive, and urinary tracts in patients.